Search Results
lovly
Christine M. Lovly, M.D.
Christine M. Lovly, M.D., Ph.D., is associate professor of medicine within the Division of Hematology and Oncology at Vanderbilt University School of Medicine and co-leader of the Translational Research and…
Emerging Therapies for New Targets for Metastatic NSCLC
As understanding of drug resistance grows, so must therapeutic strategies.
Molecular Profiling Offers Clues to Treat Rare Cancer
First-time genotyping of MPTT points to improved diagnosis, targeted therapies.
Liquid Biopsies to Identify Gene Mutations Associated with SCLC
Liquid biopsies and ctDNA shown to track SCLC progression, with widespread implications for diagnosis and treatment.
Jean-Nicolas Gallant, Ph.D.
Jean-Nicolas Gallant, Ph.D., is a trainee in the Medical Scientist Training Program at Vanderbilt University School of Medicine. He completed his Ph.D. with Christine Lovly, M.D., while studying the molecular…
Vanderbilt Oncologists Presenting at the ASCO Annual Meeting in Chicago
Vanderbilt-Ingram Cancer Center researchers are excited to share their insights with the oncology community at this year's gathering of the American Society of Clinical Oncologists. Here's where our experts are featured.
Updated Guidelines for Lung Cancer Screening Aim to Reduce Disparities
Expanded screening addresses varying risk factors and could help African Americans.
Taking Advanced Cancer Care to Rural Areas
Initiative will bring telehealth to rural providers and patients.
Ensartinib as a First-line Treatment for NSCLC
Interim results suggest advantages over crizotinib for ALK-positive disease.